236 related articles for article (PubMed ID: 1560255)
1. Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors.
Nakagawa H; Kubo S; Murasawa A; Nakajima S; Nakajima Y; Izumoto S; Hayakawa T
J Neurooncol; 1992 Feb; 12(2):111-20. PubMed ID: 1560255
[TBL] [Abstract][Full Text] [Related]
2. [Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis].
Nakagawa H; Kubo S; Murasawa A; Nakajima S; Nakajima Y; Izumoto S; Hayakawa T
No Shinkei Geka; 1991 Dec; 19(12):1135-41. PubMed ID: 1766538
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy.
van Zanten AP; Twijnstra A; Ongerboer de Visser BW; van Heerde P; Hart AA; Nooyen WJ
J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):119-23. PubMed ID: 2019836
[TBL] [Abstract][Full Text] [Related]
4. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis.
Klee GG; Tallman RD; Goellner JR; Yanagihara T
Mayo Clin Proc; 1986 Jan; 61(1):9-13. PubMed ID: 3510343
[TBL] [Abstract][Full Text] [Related]
5. CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer.
Yap BS; Yap HY; Fritsche HA; Blumenschein G; Bodey GP
JAMA; 1980 Oct; 244(14):1601-3. PubMed ID: 7420663
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biochemical markers of central nervous system metastases.
Schold SC; Wasserstrom WR; Fleisher M; Schwartz MK; Posner JB
Ann Neurol; 1980 Dec; 8(6):597-604. PubMed ID: 7212647
[TBL] [Abstract][Full Text] [Related]
7. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors.
Twijnstra A; Ongerboer de Visser BW; van Zanten AP; Hart AA; Nooyen WJ
J Neurooncol; 1989 May; 7(1):57-63. PubMed ID: 2666594
[TBL] [Abstract][Full Text] [Related]
8. Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: a pilot study in 13 patients.
Nakagawa H; Fujita T; Kubo S; Izumoto S; Nakajima Y; Tsuruzono K; Tokiyoshi K; Hayakawa T
Surg Neurol; 1996 Mar; 45(3):256-64. PubMed ID: 8638223
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of patients with meningeal carcinomatosis.
Nakagawa H; Murasawa A; Kubo S; Nakajima S; Nakajima Y; Izumoto S; Hayakawa T
J Neurooncol; 1992 May; 13(1):81-9. PubMed ID: 1613540
[TBL] [Abstract][Full Text] [Related]
10. The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer.
Wang P; Piao Y; Zhang X; Li W; Hao X
Cancer Biomark; 2013; 13(2):123-30. PubMed ID: 23838141
[TBL] [Abstract][Full Text] [Related]
11. Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor.
Nakagawa H; Fujita T; Kubo S; Tokiyoshi K; Yamada M; Kanayama T; Hagiwara Y; Nakanomyo H; Hiraoka M
Cancer Chemother Pharmacol; 1996; 37(4):317-26. PubMed ID: 8548876
[TBL] [Abstract][Full Text] [Related]
12. Added Diagnostic Value of Cerebrospinal Fluid Carcinoembryonic Antigen in a Patient with Leptomeningeal Carcinomatosis as the Initial Manifestation of Gastric Cancer.
Ino R; Sada KE; Miyauchi A; Hashimoto D; Nojima S; Yamanaka S; Kawamura M
Acta Med Okayama; 2021; 75(5):659-661. PubMed ID: 34703051
[TBL] [Abstract][Full Text] [Related]
13. [A case of leptomeningeal carcinomatosis: demonstration of CA19-9 and CEA positive malignant cells in the CSF and particular elevation of CA19-9 level in the CSF].
Sato Y; Ohta Y; Ohtsuka T; Shoji H; Oizumi K
Rinsho Shinkeigaku; 1991 Feb; 31(2):175-8. PubMed ID: 2060242
[TBL] [Abstract][Full Text] [Related]
14. [Study of meningeal carcinomatosis: diagnosis and treatment].
Nakagawa H; Murasawa A; Nakajima S; Nakajima Y; Izumoto S; Kubo S; Hayakawa T
No Shinkei Geka; 1992 Jan; 20(1):31-7. PubMed ID: 1738424
[TBL] [Abstract][Full Text] [Related]
15. Meningeal carcinomatosis: CSF cytology, immunocytochemistry and biochemical tumor markers.
Oschmann P; Kaps M; Völker J; Dorndorf W
Acta Neurol Scand; 1994 May; 89(5):395-9. PubMed ID: 8085440
[TBL] [Abstract][Full Text] [Related]
16. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer.
Fleisher M; Wasserstrom WR; Schold SC; Schwartz MK; Posner JB
Cancer; 1981 Jun; 47(11):2654-9. PubMed ID: 7260857
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.
Wasserstrom WR; Glass JP; Posner JB
Cancer; 1982 Feb; 49(4):759-72. PubMed ID: 6895713
[TBL] [Abstract][Full Text] [Related]
18. [Value of tumor markers in the cerebrospinal fluid in the diagnosis of meningeal carcinomatosis].
Shi Q; Pu CQ; Wu WP; Huang XS; Yu SY; Tian CL; Huang DH; Zhang JT
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1192-4. PubMed ID: 20501426
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal chemotherapy for patients with meningeal carcinomatosis.
Yoshida S; Morii K
Surg Neurol; 2005 Jan; 63(1):52-5; discussion 55. PubMed ID: 15639526
[TBL] [Abstract][Full Text] [Related]
20. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
